GlobalData Names BostonGene Leading Innovator in AI-Driven Drug Repurposing

GlobalData Names BostonGene Leading Innovator in AI-Driven Drug Repurposing




GlobalData Names BostonGene Leading Innovator in AI-Driven Drug Repurposing

Recognition Highlights Dedication to Innovation and the Transformative Impact of AI-driven Solutions to Advance Drug Development

WALTHAM, Mass.–(BUSINESS WIRE)–BostonGene, a leading provider of AI-driven, molecular and immune profiling solutions, today announced that it has been named a leading innovator in AI drug repurposing in a recent report published in Pharmaceutical Technology, part of the GlobalData network. The article, “Innovators in AI Drug Repurposing: Pioneering AI in the Pharmaceutical Industry,” showcases BostonGene at the forefront of innovation by leading in both geographical reach and application diversity. BostonGene’s groundbreaking contributions to the pharmaceutical industry, driven by in artificial intelligence (AI)-based and advanced bioinformatics solutions, with the company holding more than 200 patents, solidified its leadership position in total patent count.


GlobalData analyzed over 260 companies, spanning technology vendors, established pharmaceutical companies and up-and-coming start-ups engaged in the development and application of drug repurposing AI to determine their leadership ranking.

AI-driven drug repurposing, a cutting-edge approach to drug discovery and development, leverages AI-powered machine learning algorithms to identify existing drugs that may have efficacy in diseases or disease subtypes different from the original intended patient population. This innovative approach may significantly reduce the time and cost of bringing new therapies to market. BostonGene’s AI-driven solutions have already been instrumental in accelerating drug discovery and development processes. The company’s proprietary platform utilizes the power of AI to analyze vast datasets, including genetic, clinical, and molecular information, to uncover novel uses for existing therapeutics. BostonGene’s mission is to improve patient outcomes by providing customized, cost-effective solutions with fast turnaround times, to get the right drugs to the right patients.

“We are honored to be recognized as innovators in AI drug repurposing,” said Andrew Feinberg, President and CEO at BostonGene. “With hundreds of patents in our portfolio, our team is committed to harnessing the potential of AI to transform drug discovery and to benefit patients worldwide. This recognition reflects our commitment to advancing research and bringing new hope to those in need.”

BostonGene’s contributions to AI-driven drug repurposing align with its broader mission of advancing precision medicine by tailoring treatments to individual patients. By leveraging AI and bioinformatics, BostonGene unlocks the full potential of existing drugs while reducing the risks and costs associated with traditional drug development.

Pharmaceutical Technology, part of the GlobalData network, is a renowned industry publication known for its insightful coverage of the latest developments and innovations in the pharmaceutical sector. With a strong commitment to delivering timely and relevant information, Pharmaceutical Technology plays a pivotal role in informing professionals and stakeholders about the cutting-edge advancements shaping the pharmaceutical industry.

About BostonGene Corporation

BostonGene has a mission to provide transformative, AI-integrated molecular analytics and biomarker discovery for precision matching of therapies to improve the lives of patients living with cancer and other immune-related diseases. BostonGene’s service model provides customized client solutions using a multi-omic approach prioritized for real-world impact including optimized standard-of-care therapies, accelerated research and cost-effective, measurable results. BostonGene’s tests reveal key drivers of each patient’s unique disease profile, including an in-depth profile of the immune microenvironment, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each patient. For more information, visit BostonGene at http://www.BostonGene.com.

Contacts

Media Contact:

BostonGene
Erin O’Reilly

+1-617-283-2285

Erin.Oreilly@BostonGene.com